Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilostazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 7/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilostazol SCHEMBL1818013 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| Cilostazol SCHEMBL16128 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL7307973 | 0.97 | PDE3B (0.94) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| Cilostazol SCHEMBL5798390 | 0.96 | PDE3B (0.93) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| Cilostazol SCHEMBL5798394 | 0.96 | PDE3B (0.92) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL12116425 | 0.93 | PDE3B (0.86) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL30151140 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL29701270 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL30151170 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL29701268 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205369-A1 | COMBINATORIAL PHARMACOTHERAPY FOR THE RESTORATION OF NEURO-FUNCTION AND COMBINATORIAL PHARMACOLOGICAL COMPOSITION THEREFORE | NEURO-INNOVATORS, LLC. (US) | 2023-10-26 | — | — | WO | claimed |
| CN-109310688-B | Medicine for preventing and/or treating dementia | 国立研究开发法人国立循环器病研究中心 | 2023-09-01 | — | — | CN | claimed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260102416-A1 | COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF | TLCO HOLDINGS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| EP-4704983-A2 | TREATMENT OF MEMORY LOSS WITH PHOSPHODIESTERASE INHIBITORS | Cyrano Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12569493-B2 | Treatment of chemosensory dysfunction from a coronavirus infection | Cyrano Therapeutics Inc. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | CYRANO THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250290934-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | CYRANO THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12329753-B2 | Phosphodiesterase inhibitor treatment | CYRANO THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12298316-B2 | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell | CYRANO THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20220241273-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | BAYER AG (DE) | 2022-08-04 | — | — | US | disclosed |
| CN-108883112-B | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114699528-A | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022122917-A1 | THE USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-16 | — | — | WO | disclosed |
| CN-114601837-A | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220178947-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | CYRANO THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-112288775-B | Multi-target shielding tracking method based on long-term and short-term prediction model | 武汉大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-108366947-B | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114051417-A | Drug dissolution type stent | 大塚医疗器械有限公司 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | PDE2A, PDE4A, PDE3A | PDE3A 3/4885PDE3B 6/4885MEN1 2658/4885 |
| US-20220241273-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | PRKG1, PGC, PRKG2 | PDE3A 5/4885PDE3B 10/4885MEN1 4767/4885 |
| US-20260102416-A1 | COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF | PDE8B, MGLL, PDE3B | PDE3A 9/4885PDE3B 3/4885MEN1 461/4885 |
| US-12569493-B2 | Treatment of chemosensory dysfunction from a coronavirus infection | PDE2A, PDE5A, PDE3B | PDE3A 5/4885PDE3B 3/4885MEN1 2962/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | PDE3A 356/4885PDE3B 346/4885MEN1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.